Latest News
-
From the Journals
Opioids prescribed for diabetic neuropathy pain, against advice
Inappropriate first-line opioid use was found in more than 40% of patients, dropping over time but without a concurrent rise in use of recommended...
-
From the Journals
Alien cells may explain COVID-19 brain fog
Occlusion of a multitude of tiny vessels by megalokaryocytes may explain the cognitive issues seen in some patients with COVID-19 infection.
-
From the Journals
Core feature of frontotemporal dementia may aid diagnosis
White matter hyperintensities are a “core feature of FTD and Alzheimer’s disease that can contribute to cognitive problems, and not simply as a...
-
News from the FDA/CDC
FDA approves first targeted treatment for rare DMD mutation
This particular mutation of the DMD gene “is amenable to exon 45 skipping.”
-
From the Journals
Neurologic disorders ubiquitous and rising in the U.S.
Most of the rise in disease burden could be attributed to population aging, while age-standardized figures showed stroke and dementias to be level...
-
Feature
Potential COVID-19 variant surge looms over U.S.
...
-
From the Journals
Traumatic brain injury tied to long-term sleep problems
The association with sleep disorders was strongest among those with mild TBI versus a more severe brain injury.
Literature Review
-
Literature Review
New steroid dosing regimen for myasthenia gravis
Rapid tapering of prednisone is recommended in patients requiring combined corticosteroid and azathioprine therapy.
-
Literature Review
EEG data may help aid diagnosis, treatment of focal epilepsy
“A patient with epilepsy may have a unique combination of seizure rhythms that can inform the days and timing of his or her highest seizure risk...
-
Literature Review
Adherence and discontinuation limit triptan outcomes
Low rates of triptan adherence are likely caused by disappointing efficacy and/or unpleasant side effects rather than economic considerations.
-
Literature Review
Risdiplam study shows promise for spinal muscular atrophy
Besides safety, exploratory outcomes hint at clinical benefit.
-
Literature Review
Palliative care for patients with dementia: When to refer?
A systematic literature review finds few consistent criteria for referrals save for disease stage. Researchers argue that patients’ needs may be...
-
Literature Review
Despite risks and warnings, CNS polypharmacy is prevalent among patients with dementia
The risks of these medications, particularly in combination, are almost certainly greater than the potential benefits.
-
Literature Review
Neurologic drug prices jump 50% in five years
Most of the increased cost was due to rising costs for neuroimmunology drugs, mainly for those used to treat multiple sclerosis (MS).
Expert Interview
-
Expert Interview
'Living brain implants' may restore stroke mobility
Translational research may be able to restore movement to paralyzed limbs post stroke.
Conference Coverage
-
Conference Coverage
Opioid use common for pain in multiple sclerosis
“Better pain management treatment options, including nonpharmacological options, are needed for people with MS and pain.”
-
Conference Coverage
Vitamin D deficiency linked to early cognitive impairment in MS
This association might represent a marker of future disability, supporting the need for prompt supplementation.
-
Conference Coverage
Natalizumab postinfusion reactions rare; is monitoring necessary?
New findings “highlight a potential opportunity to improve and streamline the infusion and post-infusion monitoring process.”
-
Conference Coverage
Do antidepressants increase the risk of brain bleeds?
More research is needed to examine if SSRIs prescribed after a stroke may be linked to risk of a second stroke.
-
Conference Coverage
Sleep apnea and cognitive impairment are common bedfellows
“People with cognitive impairment should be assessed for sleep apnea if they have difficulty with sleep or if they demonstrate sleep-related...
-
Conference Coverage
Infections – especially urinary and kidney – are higher in MS
Among patients with MS, the infection rate was more than quadruple the rate in a control cohort.
-
Conference Coverage
Newly approved drugs offer new hope in NMOSD
Trio of medications offer relief from relapses, neurologist tells colleagues
-
Conference Coverage
Erythropoietin falls short of neuroprotection in optic neuritis
“EPO conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis as a clinically isolated syndrome.”
-
Conference Coverage
Sun exposure linked to reduced pediatric MS risk
Children should spend at least 30 minutes outdoors in the sun every day, while using adequate sun protection.
-
Conference Coverage
Novel Alzheimer’s drug slows cognitive decline in phase 2 trial
The Alzheimer’s Association is encouraged by the promising data, according to Maria Carrillo, PhD, chief science officer for the organization.
Hitting a Nerve
-
Hitting a Nerve
Is board recertification worth it?
If I’ve already passed the neurology boards three times, hopefully that means I know what I’m doing.